View in EDS

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Saved in:
Bibliographic Details
Title: Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Authors: Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St, Ste 2N35, Portland, OR, 97213, USA. Rachel.Sanborn@providence.org., Zhou C; Shanghai East Hospital/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Tang KJ; Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Cheng S; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Popat S; Royal Marsden Hospital NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK., Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Lu S; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Aguilar A; Dexeus University Hospital, Barcelona, Spain., Del Rosario Garcia Campelo M; Hospital Universitario de A Coruña, Coruña, Spain., Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama City, Japan., Lee KY; Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan., Lee SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Delmonte A; IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), Meldola, FC, Italy., Alatorre-Alexander J; Health Pharma Professional Research, México City, Mexico., Richardson G; Cabrini Health, Melbourne, VIC, Australia., Santos V; Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Dooms C; Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium., Sabari JK; NYU Langone Health, New York, NY, USA., Shu CA; Columbia University Irving Comprehensive Cancer Center, New York, NY, USA., Girard N; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France.; Paris Saclay University, Versailles, France., Mansfield AS; Mayo Clinic, Rochester, MN, USA., Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; MD Anderson Cancer Center, Houston, TX, USA., Xia Y; Johnson & Johnson, Wayne, PA, USA., Bhattacharya A; Janssen-Cilag Ltd, a Johnson & Johnson company, High Wycombe, UK., Buyukkaramikli N; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Perualila N; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Diels J; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Acharya S; Johnson & Johnson, Mumbai, India., Chandler C; Evidera, Waltham, MA, USA., Proskorovsky I; Evidera, Waltham, MA, USA., Dearden L; Janssen-Cilag Ltd, a Johnson & Johnson company, High Wycombe, UK., Wortman-Vayn H; Johnson & Johnson, Raritan, NJ, USA., Mahadevia PJ; Johnson & Johnson, Raritan, NJ, USA., Knoblauch RE; Johnson & Johnson, Spring House, PA, USA., Agrawal T; Johnson & Johnson, Spring House, PA, USA., Baig M; Johnson & Johnson, Raritan, NJ, USA., Felip E; Medical Oncology Service, Vall d'Hebron Institute of Oncology Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
Source: Targeted oncology [Target Oncol] 2025 Nov; Vol. 20 (6), pp. 979-989. Date of Electronic Publication: 2025 Nov 03.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41184595
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sanborn+RE%22">Sanborn RE</searchLink>; Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St, Ste 2N35, Portland, OR, 97213, USA. Rachel.Sanborn@providence.org.<br /><searchLink fieldCode="AU" term="%22Zhou+C%22">Zhou C</searchLink>; Shanghai East Hospital/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Tang+KJ%22">Tang KJ</searchLink>; Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cheng+S%22">Cheng S</searchLink>; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Popat+S%22">Popat S</searchLink>; Royal Marsden Hospital NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Ono+A%22">Ono A</searchLink>; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Majem+M%22">Majem M</searchLink>; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Aguilar+A%22">Aguilar A</searchLink>; Dexeus University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Del+Rosario+Garcia+Campelo+M%22">Del Rosario Garcia Campelo M</searchLink>; Hospital Universitario de A Coruña, Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Hayashi+H%22">Hayashi H</searchLink>; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama City, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+KY%22">Lee KY</searchLink>; Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lee+SH%22">Lee SH</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Delmonte+A%22">Delmonte A</searchLink>; IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), Meldola, FC, Italy.<br /><searchLink fieldCode="AU" term="%22Alatorre-Alexander+J%22">Alatorre-Alexander J</searchLink>; Health Pharma Professional Research, México City, Mexico.<br /><searchLink fieldCode="AU" term="%22Richardson+G%22">Richardson G</searchLink>; Cabrini Health, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Santos+V%22">Santos V</searchLink>; Instituto Nacional de Câncer, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Dooms+C%22">Dooms C</searchLink>; Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Sabari+JK%22">Sabari JK</searchLink>; NYU Langone Health, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Shu+CA%22">Shu CA</searchLink>; Columbia University Irving Comprehensive Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Girard+N%22">Girard N</searchLink>; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France.; Paris Saclay University, Versailles, France.<br /><searchLink fieldCode="AU" term="%22Mansfield+AS%22">Mansfield AS</searchLink>; Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Park+K%22">Park K</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Xia+Y%22">Xia Y</searchLink>; Johnson & Johnson, Wayne, PA, USA.<br /><searchLink fieldCode="AU" term="%22Bhattacharya+A%22">Bhattacharya A</searchLink>; Janssen-Cilag Ltd, a Johnson & Johnson company, High Wycombe, UK.<br /><searchLink fieldCode="AU" term="%22Buyukkaramikli+N%22">Buyukkaramikli N</searchLink>; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Perualila+N%22">Perualila N</searchLink>; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Diels+J%22">Diels J</searchLink>; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Acharya+S%22">Acharya S</searchLink>; Johnson & Johnson, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Chandler+C%22">Chandler C</searchLink>; Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Proskorovsky+I%22">Proskorovsky I</searchLink>; Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dearden+L%22">Dearden L</searchLink>; Janssen-Cilag Ltd, a Johnson & Johnson company, High Wycombe, UK.<br /><searchLink fieldCode="AU" term="%22Wortman-Vayn+H%22">Wortman-Vayn H</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Mahadevia+PJ%22">Mahadevia PJ</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Knoblauch+RE%22">Knoblauch RE</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Agrawal+T%22">Agrawal T</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Baig+M%22">Baig M</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Medical Oncology Service, Vall d'Hebron Institute of Oncology Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2025 Nov; Vol. 20 (6), pp. 979-989. <i>Date of Electronic Publication: </i>2025 Nov 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41184595
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11523-025-01182-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 979
    Titles:
      – TitleFull: Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sanborn RE
      – PersonEntity:
          Name:
            NameFull: Zhou C
      – PersonEntity:
          Name:
            NameFull: Tang KJ
      – PersonEntity:
          Name:
            NameFull: Cho BC
      – PersonEntity:
          Name:
            NameFull: Cheng S
      – PersonEntity:
          Name:
            NameFull: Popat S
      – PersonEntity:
          Name:
            NameFull: Ono A
      – PersonEntity:
          Name:
            NameFull: Lu S
      – PersonEntity:
          Name:
            NameFull: Majem M
      – PersonEntity:
          Name:
            NameFull: Aguilar A
      – PersonEntity:
          Name:
            NameFull: Del Rosario Garcia Campelo M
      – PersonEntity:
          Name:
            NameFull: Hayashi H
      – PersonEntity:
          Name:
            NameFull: Lee KY
      – PersonEntity:
          Name:
            NameFull: Lee SH
      – PersonEntity:
          Name:
            NameFull: Delmonte A
      – PersonEntity:
          Name:
            NameFull: Alatorre-Alexander J
      – PersonEntity:
          Name:
            NameFull: Richardson G
      – PersonEntity:
          Name:
            NameFull: Santos V
      – PersonEntity:
          Name:
            NameFull: Dooms C
      – PersonEntity:
          Name:
            NameFull: Sabari JK
      – PersonEntity:
          Name:
            NameFull: Shu CA
      – PersonEntity:
          Name:
            NameFull: Girard N
      – PersonEntity:
          Name:
            NameFull: Mansfield AS
      – PersonEntity:
          Name:
            NameFull: Park K
      – PersonEntity:
          Name:
            NameFull: Xia Y
      – PersonEntity:
          Name:
            NameFull: Bhattacharya A
      – PersonEntity:
          Name:
            NameFull: Buyukkaramikli N
      – PersonEntity:
          Name:
            NameFull: Perualila N
      – PersonEntity:
          Name:
            NameFull: Diels J
      – PersonEntity:
          Name:
            NameFull: Acharya S
      – PersonEntity:
          Name:
            NameFull: Chandler C
      – PersonEntity:
          Name:
            NameFull: Proskorovsky I
      – PersonEntity:
          Name:
            NameFull: Dearden L
      – PersonEntity:
          Name:
            NameFull: Wortman-Vayn H
      – PersonEntity:
          Name:
            NameFull: Mahadevia PJ
      – PersonEntity:
          Name:
            NameFull: Knoblauch RE
      – PersonEntity:
          Name:
            NameFull: Agrawal T
      – PersonEntity:
          Name:
            NameFull: Baig M
      – PersonEntity:
          Name:
            NameFull: Felip E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1776-260X
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Targeted oncology
              Type: main
ResultId 1